Immune Response News and Research

RSS

Nexvax2- coeliac disease vaccine shows promising results in Phase I clinical trial

The world's first potential vaccine for coeliac disease has shown promising results for treating coeliac disease in a Phase I clinical trial and is expected to move to Phase II trials within the next year.

10 May 2011

Inovio reports VGX-3100 Phase I study data in cervical dysplasia and cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of immune responses induced by VGX-3100, its investigational DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus.

9 May 2011

KFA announces plans for charity Game-A-Thon and food allergy campaign

Kids With Food Allergies Foundation today announced plans for a charity Game-A-Thon and the Faces of Food Allergies Campaign in honor of National Asthma and Allergy Awareness Month, which includes Food Allergy Awareness Week from May 8-14.

7 May 2011

Current Opinion in Immunology journal publishes Inovio's article on DNA vaccines

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the prestigious journal Current Opinion in Immunology has published an article in its current issue entitled, "Electroporation Delivery of DNA Vaccines: Prospects for Success."

7 May 2011

Latest research on HIV immunity can help develop vaccine

Latest insights into immunity to HIV could help to develop a vaccine to build antibodies' defences against the disease, a University of Melbourne, Australia study has found.

7 May 2011

Researchers find temperature-sensing protein in immune cells

Researchers at The Scripps Research Institute have found a temperature-sensing protein within immune cells that, when tripped, allows calcium to pour in and activate an immune response.

7 May 2011

Neutralizing antibodies generated by immunization associated with protection against SIV infection

Using a monkey model of AIDS, scientists have identified a vaccine-generated immune-system response that correlates with protection against infection by the monkey version of HIV, called simian immunodeficiency virus (SIV). The researchers found that neutralizing antibodies generated by immunization were associated with protection against SIV infection.

6 May 2011

Researchers identify key mucus component in human gut that can kill parasitic worms

Scientists have discovered why some people may be protected from harmful parasitic worms naturally while others cannot in what could lead to new therapies for up to one billion people worldwide.

5 May 2011

Researchers identify regulatory protein that can inhibit cancer metastasis

A protein capable of halting the spread of breast cancer cells could lead to a therapy for preventing or limiting the spread of the disease.

5 May 2011

New nano-vault delivery system can fight cancer

UCLA scientists have discovered a way to wake up the immune system to fight cancer by delivering an immune system-stimulating protein in a nanoscale container called a vault directly into lung cancer tumors, harnessing the body's natural defenses to fight disease growth.

4 May 2011

Scientists discover how immune cells recognize invading pathogens in the body

Scientists at Cedars-Sinai Medical Center have discovered how a molecular receptor on the surface of white blood cells identifies when invading fungi have established direct contact with the cell surface and pose an infectious threat.

30 Apr 2011

Flu vaccination lowers kidney transplant recipients' risk of organ loss and death

Getting vaccinated against the flu lowers kidney transplant recipients' risk of organ loss and death, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

29 Apr 2011

Researchers begin approved drugs screening for clinical use against rare diseases

Researchers have begun screening the first definitive collection of thousands of approved drugs for clinical use against rare and neglected diseases. They are hunting for additional uses of the drugs hoping to find off-label therapies, for some of the 6,000 rare diseases that afflict 25 million Americans.

28 Apr 2011

Promising pain medication may decrease ability to fight off sepsis

Pain researchers from the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Medical Center have discovered that resiniferatoxin, a drug that has shown early promise as an option for chronic, severe pain sufferers, may decrease the body's ability to fight off bacterial infections, particularly sepsis.

27 Apr 2011

ProtoKinetix, Imaginative Research Associates partner to formulate topical anti-inflammation product

ProtoKinetix, is pleased to announce, that it has entered into a Joint Venture Agreement with Imaginative Research Associates, Inc. to formulate a topical anti-inflammation product for the skin care market.

27 Apr 2011

Study finds gender difference in immune responses to PTSD

Men and women had starkly different immune system responses to chronic post-traumatic stress disorder, with men showing no response and women showing a strong response, in two studies by researchers at the San Francisco VA Medical Center and the University of California, San Francisco.

27 Apr 2011

Signaling pathway reveals mechanism for B cell differentiation in immune response

An article in Science Signaling by researchers at the RIKEN Research Center for Allergy and Immunology (RCAI) has clarified for the first time the mechanism governing differentiation of B cells into antibody-producing plasma cells. The finding establishes a role for the extracellular signal-regulated kinase (ERK) signaling pathway in B cell differentiation, a key step toward the development of B cell-targeted drugs for treatment of autoimmune diseases and allergies.

25 Apr 2011

NovaSterilis novel vaccine patent

NovaSterilis Inc., a leader in the development and commercialization of supercritical carbon dioxide technology, has been granted US Patent 7,919,096. The patent, dated April 5th 2011, is entitled “Inactivating Organisms Using Carbon Dioxide At or Near Supercritical Pressure and Temperature Conditions.”

25 Apr 2011

FDA approves Sanofi Pasteur's meningococcal vaccine

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration has granted licensure to expand the indication for its meningococcal conjugate vaccine, Menactra, to include a two-dose schedule for infants and children 9 months through 23 months of age.

25 Apr 2011

GM-CSF appears to be key culprit in multiple sclerosis onset

Reporting in Nature Immunology, Jefferson neuroscientists have identified a driving force behind autoimmune diseases such as multiple sclerosis, and suggest that blocking this cell-signaling molecule is the first step in developing new treatments to eradicate these diseases.

25 Apr 2011

Immune Response News and Research

Nexvax2- coeliac disease vaccine shows promising results in Phase I clinical trial

Inovio reports VGX-3100 Phase I study data in cervical dysplasia and cancer

KFA announces plans for charity Game-A-Thon and food allergy campaign

Current Opinion in Immunology journal publishes Inovio's article on DNA vaccines

Latest research on HIV immunity can help develop vaccine

Researchers find temperature-sensing protein in immune cells

Neutralizing antibodies generated by immunization associated with protection against SIV infection

Researchers identify key mucus component in human gut that can kill parasitic worms

Researchers identify regulatory protein that can inhibit cancer metastasis

New nano-vault delivery system can fight cancer

Scientists discover how immune cells recognize invading pathogens in the body

Flu vaccination lowers kidney transplant recipients' risk of organ loss and death

Researchers begin approved drugs screening for clinical use against rare diseases

Promising pain medication may decrease ability to fight off sepsis

ProtoKinetix, Imaginative Research Associates partner to formulate topical anti-inflammation product

Study finds gender difference in immune responses to PTSD

Signaling pathway reveals mechanism for B cell differentiation in immune response

NovaSterilis novel vaccine patent

FDA approves Sanofi Pasteur's meningococcal vaccine

GM-CSF appears to be key culprit in multiple sclerosis onset

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News